BERUBE BRIAN A
Known title: SVP and General CounselCIK: 0001243739
Associated companies
Transaction History
| AXTA | ▼ Sell | Open Market | 7,500 | $234K | 11/17/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 22,366 | — | 7/27/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 9,920 | $318K | 7/27/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 4,565 | — | 3/3/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 2,025 | $63K | 3/3/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 4,261 | — | 2/19/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,890 | $56K | 2/19/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 5,089 | — | 2/15/2023 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 2,387 | $71K | 2/15/2023 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 3,134 | — | 6/14/2022 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,390 | $34K | 6/14/2022 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 4,938 | $119K | 6/14/2022 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 11,134 | — | 6/14/2022 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 4,565 | — | 3/3/2022 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 2,025 | $52K | 3/3/2022 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 4,261 | — | 2/19/2022 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,890 | $55K | 2/19/2022 | View on chart |
| AXTA | ▲ Buy | Option Exercise | 6,183 | — | 2/15/2022 | View on chart |
| AXTA | ▼ Sell | Tax Withholding | 1,924 | $55K | 2/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
UBS Cuts Axalta Price Target to $36, Maintains Neutral Rating
UBS lowered its price target for Axalta to $36 while keeping a neutral stance. The company also announced the date for its third-quarter 2026 earnings call. These updates provide new context as Axalta trades near its 52-week low, with the stock currently sitting above a key support level.
UBS Cuts Axalta Price Target to $36, Maintains Neutral Rating. UBS lowered its price target for Axalta to $36 while keeping a neutral stance. The company also announced the date for its third-quarter 2026 earnings call. These updates provide new context as Axalta trades near its 52-week low, with the stock currently sitting above a key support level.